SB

Sagimet Biosciences Inc.

SGMT·NASDAQ

$6.86

+1.3%
HealthcareBiotechnology

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

At a Glance

Live Snapshot
Market Cap$223.51M
EPS-1.5800
P/E Ratio-4.34
Earnings Date08/12/2026

sgmt

Change in Working Capital

Last Annual Value

-1.05M

3-Year CAGR

-8%

5-Year CAGR

-72%

10-Year CAGR

-10%

SB

Sagimet Biosciences Inc. Competitors Analysis of Change in Working Capital

SGMT · NASDAQ
CompanyChange in Working Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
-1.05M
N/AN/AN/A 
-28.76M
N/AN/AN/A
16.48M
0.7%N/AN/A
-38.28M
N/AN/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
-23.39M
N/AN/AN/A
-484.00K
N/AN/AN/A
39.91M
70.7%N/A20.5%
-4.08M
N/AN/AN/A
-39.20M
N/AN/AN/A
-32.14M
N/AN/AN/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
-3.63M
N/AN/AN/A
SB

Sagimet Biosciences Inc. Fair Value Envelope

SGMT · NASDAQ

Our analysis suggests that SGMT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.86, this represents a potential HIDDEN relative to our calculated worth for Sagimet Biosciences Inc..

Intrinsic Value
Current Price: $6.86